Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ganji is a Traditional Chinese Medicine (TCM) formulation composed of 14 herbal extracts, primarily investigated as an adjuvant therapy for hepatocellular carcinoma (HCC) patients who have undergone surgery. Clinical studies suggest it can improve postoperative cumulative survival and prolong the time to disease progression (TTP) in HCC patients. Its proposed mechanisms of action include inhibiting cell proliferation and migration, inducing apoptosis, and regulating the cell cycle, potentially through the inhibition of the PI3K/Akt signaling pathway and down-regulation of ARPP-19 expression. It is also believed to have beneficial effects on spleen detoxification and general anticancer functions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ganji.